Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 06-BG; Alkylade; BG; KRX 0402; NSC 638037; O6-benzylguanine

Latest Information Update: 01 Mar 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA); The Pennsylvania State University
  • Developer ACCESS Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Chemosensitisers; Hypoxanthines; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cutaneous T-cell lymphoma
  • Discontinued Brain cancer; Glioblastoma; Glioma; Multiple myeloma; Sarcoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Feb 2017 National Cancer Institute completes a phase-I/II clinical trial in Cutaneous T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT00961220)
  • 10 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top